CRISM THERAPEUTICS CORPORATION (CRTX) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the CRISM THERAPEUTICS CORPORATION investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Andrew Webb, CEO. Good afternoon, sir. Good afternoon. Welcome to today's CRISM THERAPEUTICS CORPORATION. Thank you very much for take taking the time today. My name is Andrew Webb, and the purpose of today's presentation is to update you on the significant progress we've made over recent months. Those of you who may recall the present to last update was in September. And clearly, for today, it's in the context of seeking additional funding through from our existing shareholders through a retail offer which was published. This is a follow on from a successful and oversubscribed placing, which the company did earlier in the week. So as far as introduction, just a refresher. CRISM THERAPEUTICS, we are a drug delivery company working on how we can improve, importantly, the safety and efficacy of chemotherapy for for cancer patients. If I may just by virtue of an overview, just as a refresh, we are ourselves a platform drug delivery company. So we believe the technology that we have is, which is certainly Quemacy, will be available to and accessible to a number number of solid tumor indications. What we're doing at the moment, as alw...